15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English OR models of hepatitis B prove decisive in treating ...
查看: 802|回复: 2
go

OR models of hepatitis B prove decisive in treating millions in US, China [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2011-7-31 12:45 |只看该作者 |倒序浏览 |打印
本帖最后由 StephenW 于 2011-7-31 12:46 编辑

http://medicalxpress.com/news/2011-07-hepatitis-decisive-millions-china.html
OR models of hepatitis B prove decisive in treating millions in US, China                                July 26, 2011                                                                                                  

With hepatitis B infecting as many as 10% of people of Asian descent, operations researchers collaborated with a liver transplant surgeon to develop mathematical models that verified the cost effectiveness of hepatitis B interventions. These interventions now successfully screen, treat, and vaccinate millions of Asian and Pacific Islander adults in the U.S. and millions of children in China, according to a paper in a journal of the Institute for Operations Research and the Management Sciences (INFORMS).                                       


Untreated, hepatitis B can become a chronic, lifelong disease that leads to liver cancer and cirrhosis.
Chinese health officials were considering a program of catch-up vaccinations for children who had not been vaccinated at birth, but were reluctant to commit funds to a widespread hepatitis B catch-up vaccination program until analysis confirmed its cost-effectiveness.
The authors' analysis of the program's cost effectiveness influenced the Chinese government's April 2009 decision to expand free catch-up vaccination to all children in China under the age of 15.
They estimate that this decision could result in almost 170 million children being vaccinated and could prevent almost 8 million acute infections, 400,000 chronic infections, and almost 70,000 deaths. The vaccinations would cost the equivalent of $540 million and save the equivalent of $1.4 billion over the lifetime of these children, for a net present savings of approximately $900 million.
Additionally, they would spare hundreds of thousands of Chinese children from facing a lifetime of discrimination – those infected with hepatitis B in China, according to reports, are often denied the right to attend school or enter the workplace.
In the U.S., they evaluated four clinical strategies. Of the four, they concluded that it is most cost-effective to adopt a strategy of screening adult Asian and Pacific Islanders for chronic hepatitis B infection so that those identified can receive treatment. They also found it cost-effective to vaccinate those in close contact with the infected so they can be protected from contagion.
"Doing Good with Good O.R. [Operations Research]: Supporting Cost-Effective Hepatitis B Interventions" is by David W. Hutton and Margaret L. Brandeau of the Department of Management Science and Engineering at Stanford University and Samuel K. So of the Stanford University School of Medicine's Asian Liver Center and Department of Surgery. It appears in a special issue of the INFORMS journal Interfaces that is dedicated to the new, growing field of humanitarian applications in operations research, which applies analytical and mathematical models to benefit the public sector.

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2011-7-31 12:47 |只看该作者
本帖最后由 StephenW 于 2011-7-31 12:47 编辑

谷歌翻译不是100%正确,仅供参考使用。

随着B型肝炎感染多达10%的亚裔人,肝脏移植外科医生操作的研究人员合作开发,验证了B型肝炎干预的成本效益的数学模型。这些干预措施,现在已经成功地屏,治疗,接种疫苗数以百万计的亚洲和太平洋岛民在美国和在中国数以百万计的儿童的成年人,根据一个文件中的运筹学与管理科学(运筹学)研究所期刊。

未经处理的,乙肝可以成为一种慢性,终身性疾病,导致肝癌和肝硬化。

中国卫生官员正在考虑追赶谁​​没有接种疫苗的儿童出生时接种疫苗计划,但不愿投入资金一个普遍的肝炎乙追赶疫苗接种计划,直到分析证实其成本效益。

作者“计划的成本效益分析的影响2009年4月中国政府决定扩大在15岁以下免费追赶注射疫苗,以在中国的所有儿童。

他们估计,这一决定可能导致近170万儿童预防接种,并可以防止急性感染近800万,40万慢性感染,近70000人死亡。疫苗接种工作将花费相当于540万美元,并节省了相当于14亿美元,目前为约900万美元的净储蓄,这些孩子的一生。

此外,他们将不遗余力成千上万的中国儿童面临歧视的一生 - 与中国B型肝炎感染者,据报道,经常被剥夺的权利,上学或输入工作场所。
在美国,他们评估了四个临床策略。之四,他们得出的结论,这是最具成本效益,采用筛选成人亚洲和太平洋岛民,以便确定那些可以接受治疗的慢性乙肝病毒感染的策略。他们还发现它符合成本效益的疫苗接种与感染者密切接触的人士,使他们能够从传染的保护。
“行善良好或[运筹学]:支持成本效益的B型肝炎干预”是由David W.赫顿的,管理科学与工程部和Margaret L. Brandeau因此,斯坦福大学的斯坦福大学和Samuel K.学校的医学院的亚洲肝病中心和外科部。看来通知杂志接口,致力于新的,越来越多的人道主义行动的研究,它适用于分析和数学模型,以造福于公共部门的应用领域中的特殊问题。

Rank: 4

现金
17 元 
精华
帖子
2 
注册时间
2011-7-10 
最后登录
2012-5-17 
3
发表于 2011-7-31 15:06 |只看该作者
GCD根本不管老百姓死活 ,疫苗这种东西都怕花钱,我们要是早接种 ,今天那会过的这么无奈
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-11-16 13:40 , Processed in 0.013767 second(s), 11 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.